Ogadimma Arisukwu | cancer | Editorial Board Member

Published on by Oncology

Dr. Ogadimma Arisukwu | cancer | Editorial Board Member

Research Scholar | Landmark University | Nigeria

Dr. Ogadimma Arisukwu is an accomplished social scientist and lecturer at Landmark University, Omu-Aran, Nigeria, whose scholarship spans social policy, public health systems, community studies, and socio-cultural dynamics within African societies. His research examines the intersection of governance, health service delivery, livelihood realities, and culturally rooted behavioral responses, with a particular focus on how institutional structures shape societal well-being. Dr. Arisukwu’s work offers evidence-based insights into contemporary sociological challenges, including health insurance utilization, socio-cultural perceptions of reproductive technologies, and emerging threats such as employment scams that affect vulnerable populations. His publications demonstrate strong methodological rigor, integrating qualitative and quantitative approaches to understand lived experiences, inform policy reforms, and strengthen community resilience. As an active academic contributor, he has authored numerous peer-reviewed studies in reputable international journals, contributing to global debates on health equity, social justice, and cultural determinants of human behavior. Dr. Arisukwu engages in interdisciplinary collaborations with scholars across Nigeria and beyond, promoting research that bridges academic inquiry and practical societal needs. His work carries substantial societal relevance, supporting better-informed policymaking, advancing inclusive healthcare practices, and deepening understanding of cultural frameworks that shape public perception and behavior. Through sustained research productivity and community-centered academic engagement, he has established himself as a respected voice in sociology and social policy research. Dr. Arisukwu’s academic influence and research productivity are reflected in his metrics 212 citations, 31 documents, and an h-index of 9.

Profiles: Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Job scams in Ibadan (2024) Arisukwu, O., et al. (2024). Job advertisements and lived experiences of victims of job scams in Ibadan, Nigeria. International Journal of Sociology and Social Policy.
(Citations: 2)

2. NHIS–HMO healthcare perception (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Healthcare service delivery perception among NHIS-HMO enrollees in Lagos hospitals. Humanities and Social Sciences Communications. (Citations: 2)

3. Religious & cultural interpretations of artificial insemination (2023) Authors include: Arisukwu, O., et al. (2023). Religious and cultural interpretations of artificial insemination in South-West Nigeria. AJOG Global Reports. (Citations: 4)

4. Attitudes of medical personnel in Lagos hospitals (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Perception among NHIS–HMO enrolees of the attitudes of medical personnel during outpatient care in Lagos hospitals. International Journal of Environmental Research and Public Health, 20(2). https://doi.org/10.3390/ijerph20021218

5. Youth gambling in Nigeria (2021)

Adebisi, T., Alabi, O., Arisukwu, O., & Asamu, F. (2021). Gambling in transition: Assessing youth narratives of gambling in Nigeria. Journal of Gambling Studies. https://doi.org/10.1007/s10899-020-09982-x

Luis Rico | Oncology | Editorial Board Member

Published on by Oncology

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Niyaz Ahmad | Oncology | Editorial Board Member

Published on by Oncology

Assist. Prof. Dr. Niyaz Ahmad | Oncology | Editorial Board Member

Assistant Professor | Imam Abdulrahman Bin Faisal University | Saudi Arabia

Dr. Niyaz Ahmad is a distinguished researcher and academic at Buraydah Private Colleges, Saudi Arabia, with extensive expertise in nanomedicine, drug delivery systems, neuropharmacology, and translational therapeutics. His research focuses on designing and optimizing nanoemulsions, polymeric nanoparticles, and mucoadhesive formulations for the treatment of neurological, psychiatric, metabolic, and dermatological disorders. Dr. Ahmad has contributed to advancing therapeutic strategies through innovative delivery platforms that enhance bioavailability, target specificity, and efficacy while minimizing systemic side effects. His work encompasses in vitro, in vivo, and pharmacokinetic studies, reflecting a comprehensive approach to preclinical development and translational research. He has authored over 108 publications in high-impact journals such as ACS Omega, RSC Advances, Polymer Bulletin, and the Journal of Drug Delivery Science and Technology, demonstrating his leadership in multidisciplinary collaborations with more than 260 co-authors globally. Dr. Ahmad’s contributions have significantly impacted drug formulation science, therapeutic innovation, and patient-centered translational research, bridging molecular science and clinical application to address complex health challenges. His research has informed novel strategies in nanomedicine that are poised to improve therapeutic outcomes for a range of disorders, highlighting his societal influence in biomedical research. Dr. Ahmad’s academic influence and research productivity are reflected in his metrics—3,209 citations, 108 documents, and an h-index of 35, illustrating his sustained and global scholarly impact.

Profiles: Scopus | ORCID

Featured Publications

1. Nanoemulsion of Pioglitazone (Diabetes & Skin Diseases) Author(s). (2024). Development of novel nanoemulsion of pioglitazone used in the treatment of diabetes and its gel form for the treatment of skin diseases. Journal of Drug Delivery Science and Technology. Citations: 4

2. Mucoadhesive Paliperidone Nanoemulsion (Schizophrenia) Author(s). (2024). A novel mucoadhesive paliperidone-nanoemulsion developed using the ultrasonication method in the treatment of schizophrenia. RSC Advances.Citations: 2

3. Mangiferin PLGA Nanoparticles (Cerebral Ischemia) Author(s). (2024). Development and evaluation of polysorbate-80 coated Mangiferin PLGA nanoparticles used in the treatment of cerebral ischemia. Polymer Bulletin.Citations: 5

4. S-allyl Cysteine Chitosan Nanoparticles (Ischemic Brain Treatment) Author(s). (2024). Preparation of novel S-allyl cysteine chitosan-based nanoparticles for use in ischemic brain treatment. RSC Advances.
Citations: 6

5. Review on Diabetes (Diagnostics & Future Horizons)

Author(s). (2024). Unveiling diabetes: Categories, genetics, diagnostics, treatments, and future horizons. [Journal details not provided].
Citations: 3
h-index of author: 35

Shahanavaj Khan | Cancer Science | Editorial Board Member

Published on by Oncology

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

Hifzur R Siddique | Cancer Science | Editorial Board Member

Published on by Oncology

Assist. Prof. Dr. Hifzur R Siddique | Cancer Science | Editorial Board Member

Assistant Professor | Aligarh Muslim University | India

Dr. Hifzur R. Siddique is a distinguished researcher and academic at Aligarh Muslim University, India, specializing in cancer biology, nanomedicine, stem cell research, chemoresistance mechanisms, and translational therapeutics. His work spans the synthesis and characterization of metal oxide nanoparticles with anticancer potential, epigenetic regulation in cancer, and preclinical evaluation of natural compounds like lupeol for chemotherapeutic applications. Dr. Siddique has contributed significantly to methodological advancements, including the use of Drosophila melanogaster models for DNA damage studies and luciferase-based reporter assays for kinase activity assessment. With a robust portfolio of 103 publications in high-impact journals, book chapters, and systematic reviews, he collaborates extensively with over 340 co-authors worldwide, reflecting his leadership in multidisciplinary cancer research. His studies not only advance fundamental understanding of tumor biology but also address translational challenges, bridging laboratory findings to clinical and societal impact. Dr. Siddique’s research has influenced global guidelines on rare malignancies such as NUT carcinoma and contributed to the development of nanocomposite-based therapeutic strategies. His work embodies a commitment to improving cancer outcomes, fostering innovation, and mentoring the next generation of scientists in oncology and biomedical sciences. Dr. Siddique’s academic influence and research productivity are reflected in his metrics 3,083 citations, 103 documents, and an h-index of 30.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

Siddique, H. R., & Saleem, M. (2011). Beneficial health effects of lupeol triterpene: A review of preclinical studies. Life Sciences, 88(7-8), 285–293. [Cited by 477]

Siddique, H. R., & Saleem, M. (2012). Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences. Stem Cells, 30(3), 372–378. [Cited by 419]

Mishra, S. K., Siddique, H. R., & Saleem, M. (2012). S100A4 calcium-binding protein is key player in tumor progression and metastasis: Preclinical and clinical evidence. Cancer and Metastasis Reviews, 31(1), 163–172. [Cited by 212]

Siddique, H. R., Chowdhuri, D. K., Saxena, D. K., & Dhawan, A. (2005). Validation of Drosophila melanogaster as an in vivo model for genotoxicity assessment using modified alkaline Comet assay. Mutagenesis, 20(4), 285–290. [Cited by 146]

Fatma, H., Maurya, S. K., & Siddique, H. R. (2022). Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance. Seminars in Cancer Biology, 83, 166–176. [Cited by 136]

Jun Lu | Cancer | Editorial Board Member

Published on by Oncology

Prof. Jun Lu | Cancer | Editorial Board Member

Professor | Chengdu University of Traditional Chinese Medicine | China

Dr. Jun Lu is a distinguished researcher at Chengdu University of Traditional Chinese Medicine, China, specializing in cancer nanomedicine, biomaterials, and translational therapeutics. His work focuses on the design and development of multifunctional nanoplatforms, including engineered chitosan nanoparticles, aptamer-conjugated chemotherapeutics, and self-gelling biomaterials for applications in tumor therapy, wound healing, and infectious disease management. Dr. Lu integrates molecular biology, materials science, and bioengineering to advance innovative therapeutic strategies, such as modulating tumor microenvironments, orchestrating DNA damage pathways in colorectal carcinoma, and promoting MRSA-infected wound healing. He has authored 78 publications in high-impact journals including Journal of Translational Medicine, Chemical Engineering Journal, Carbohydrate Polymers, and Nano Research, reflecting strong expertise in nanobiotechnology and translational oncology. His extensive collaborations with over 380 co-authors worldwide demonstrate his leadership in multidisciplinary research networks, bridging fundamental science with clinical applications. Beyond academic contributions, Dr. Lu’s work has significant societal impact by enabling advanced therapies for cancer, infectious diseases, and tissue repair, providing novel solutions to global health challenges. His research emphasizes translational relevance and real-world applicability, contributing to safer, more effective, and innovative therapeutic modalities. Dr. Lu’s academic influence and research productivity are reflected in his metrics 2,421 citations, 78 documents, and an h-index of 24.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

Lu, J., Zhang, H., Hou, J., Li, X., Hu, X., Hu, Y., Easton, C. D., Li, Q., Sun, C., … (2020). Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks. Nature Materials, 19(7), 767–774. Cited by: 495

Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., Zhang, G. (2017). Chemical modifications of nucleic acid aptamers for therapeutic purposes. International Journal of Molecular Sciences, 18(8), 1683. Cited by: 384

Lu, J., Jiang, F., Lu, A., Zhang, G. (2016). Linkers having a crucial role in antibody–drug conjugates. International Journal of Molecular Sciences, 17(4), 561. Cited by: 352

Tan, C. M., Therien, A. G., Lu, J., Lee, S. H., Caron, A., Gill, C. J., Lebeau-Jacob, C., … (2012). Restoring Methicillin-Resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Science Translational Medicine, 4(126), 126ra35.
Cited by: 328

Li, F., Lu, J., Liu, J., Liang, C., Wang, M., Wang, L., Li, D., Yao, H., Zhang, Q., Wen, J., … (2017). A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications, 8(1), 1390.
Cited by: 275

 

Sheeba Irshad | Tumour Immunology | Editorial Board Member

Published on by Oncology

Dr. Sheeba Irshad | Tumour Immunology | Editorial Board Member

Senior Clinical Lecturer | King’s College London | United Kingdom

Dr. Sheeba Irshad is a distinguished clinician-scientist at Guy’s Hospital, London, specializing in translational oncology, tumor immunology, and precision medicine, with a strong focus on breast cancer, immune surveillance, therapeutic resistance, oncolytic viro-immunotherapy, and treatment-related toxicities. Her pioneering work advances immune-based therapeutic innovation through Fc-engineered antibodies, viral vaccine–driven T-cell activation, immunomodulatory gene therapies, and strategies aimed at reversing T-cell exhaustion in poorly immunogenic tumors. She has authored 61 publications in leading journals such as Cancer Research, Molecular Therapy, Translational Oncology, and PLOS ONE, addressing critical challenges including breast cancer cardiotoxicity, radiation-induced fibrosis, and the complex interplay between viral immunity and tumor control. Dr. Irshad’s extensive global collaborations—spanning more than 1,300 co-authors—demonstrate her leadership within multidisciplinary cancer research networks and her commitment to integrating molecular biology, immunology, and clinical oncology to accelerate therapeutic translation. Her contributions have significantly influenced the development of safer and more effective immunotherapies, improving patient outcomes and shaping modern oncology practice worldwide. Dr. Irshad’s academic influence and research productivity are reflected in her metrics 2,293 citations, 61 documents, and an h-index of 22.

Profiles: Scopus| ORCID | LinkedIn

Featured Publications

Cheung, A., Chenoweth, A. M., Johansson, A., Laddach, R., Guppy, N., Trendell, J., Esapa, B., Mavousian, A., Navarro-Llinas, B., Haider, S., et al. (2024). Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth. Clinical Cancer Research.

Hsu, R., Al-Zubeidy, B., Flores, D., Nazarian, A., Baugh, A., Gonzalez, E., Castanon, S., Xiu, J., Kang, I., Spicer, D., et al. (2024). Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast-to-liver metastases in breast cancer. Breast Cancer Research and Treatment.

Jahangir, C. A., Page, D. B., Broeckx, G., Gonzalez, C. A., Burke, C., Murphy, C., Reis-Filho, J. S., Ly, A., Harms, P. W., Gupta, R. R., et al. (2024). Image-based multiplex immune profiling of cancer tissues: Translational implications. Report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology.

Tang, C. C., Timbres, J., Ramsey, K., Mera, A., Irshad, S., Sawyer, E., & Khan, A. (2023). Clinico-pathological co-variates define a predictive model of breast cancer-related lymphoedema (BCRL) in patients undergoing axillary surgery for breast cancer. Cancer Research.

Fatayer, H., O’Connell, R. L., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., Gardiner, M. D., Grayson, M., Holcombe, C., et al. (2023). Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study (Vol. 109, p. 800, 2022). BJS.

Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Published on by Oncology

Dr. Kimihide Kusafuka | Neck Cancer | Editorial Board Member

Clinical Physician | Shizuoka General Hospital | Japan

Dr. Kimihide Kusafuka is a distinguished pathologist at Shizuoka General Hospital, Japan, internationally recognized for his expertise in head and neck pathology, salivary gland tumors, and molecular oncopathology. His research has been instrumental in redefining diagnostic criteria, histopathological classifications, and gene alteration profiles across a spectrum of rare and aggressive neoplasms. Dr. Kusafuka has contributed significantly to the understanding of salivary duct carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and solitary fibrous tumors through large-cohort analyses, multi-institutional collaborations, and advanced molecular techniques, including MYB/MYBL1 rearrangement characterization, CRTC1/3-MAML2 fusion analysis, and the identification of novel tumor variants. His scholarly output comprises 100 peer-reviewed documents, reflecting a sustained commitment to translational pathology and precision diagnostics. With more than 380 collaborators worldwide, his work has shaped global guidelines, influenced tumor classification systems, and improved prognostic assessment models for clinicians and researchers in the field. Dr. Kusafuka’s studies spanning molecular pathology, surgical pathology, and carcinoma outcome prediction—continue to strengthen diagnostic accuracy and therapeutic decision-making, ultimately improving patient outcomes and contributing to the advancement of cancer pathology. His rigorous methodologies, cross-disciplinary partnerships, and leadership in multi-center Japanese cohorts highlight his role as a leading figure in contemporary oncologic pathology. Dr. Kusafuka’s academic influence and research productivity are reflected in his metrics: 1,768 citations, 100 documents, and an h-index of 25.

Profiles: Scopus| ORCID | ResearchGate

Featured Publications

Kusafuka, K., et al. (2022). A symptomatic intercalated duct lesion of the parotid gland: A case report with immunohistochemical and genetic analyses. Medical Molecular Morphology. Citations: 2

Kusafuka, K., et al. (2022). Salivary gland polymorphous adenocarcinoma: Clinicopathological features and gene alterations in 36 Japanese patients. Journal of Oral Pathology and Medicine.Citations: 6

Kusafuka, K., et al. (2022). Intraoral basal cell carcinoma of the soft palate: A diagnostic pitfall. Citations: 2

Kusafuka, K., et al. (2022). The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan. Head & Neck.  Citations: 12

Kusafuka, K., et al. (2022). Salivary mucoepidermoid carcinoma: Histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features. Histopathology. Citations: 28

George Kroumpouzos | Skin Oncology | Editorial Board Member

Published on by Oncology

Prof. Dr. George Kroumpouzos | Skin Oncology | Editorial Board Member

Professor | Jundiai Medical School, Brazil / Alpert Medical School of Brown University, USA |  United States

Dr. George Kroumpouzos is an internationally recognized dermatologist affiliated with The Warren Alpert Medical School of Brown University, United States, known for his extensive contributions to medical, surgical, cosmetic, and psychocutaneous dermatology, with a strong recent focus on the integration of artificial intelligence, large language models, and virtual reality into diagnostic and therapeutic practices. He has authored 162 peer-reviewed publications, covering clinically significant topics such as counterfeit botulinum toxin and cosmetic iatrogenic botulism, Er:YAG laser therapy for vulvovaginal atrophy in breast cancer survivors, exosome-based treatments for pattern hair loss, AI-driven innovations in maternal–fetal dermatology, and advanced nonsurgical rhinoplasty techniques. His broad collaborative network spanning more than 200 researchers globally highlights his commitment to interdisciplinary advancement across dermatology, aesthetic medicine, oncology, psychology, and women’s health. Dr. Kroumpouzos’s scholarly work consistently promotes patient safety, diagnostic accuracy, and equitable access to cutting-edge dermatologic care, positioning him as a leading voice in regulatory reform and digital transformation within the field. His global impact is underscored by his ability to bridge clinical insight with emerging technologies, shaping future standards and addressing diverse patient needs across populations. Dr. Kroumpouzos’s academic influence and research productivity are reflected in his metrics: 2,695 citations, 162 documents, and an h-index of 28.

profiles: Scopus| ORCID | ResearchGate

Featured Publications

Türk, C. B., Mirza, F. N., & Kroumpouzos, G. (2023). A screening proposal for Zoom dysmorphia in virtual settings. Life, 13(8), Article 1678.

Bhargava, S., Yumeen, S., Henebeng, E., & Kroumpouzos, G. (2022). Erosive pustular dermatosis: Delving into etiopathogenesis and management. Life, 12(12), Article 2097.

Kroumpouzos, G., Paroikaki, M. E., Yumeen, S., Bhargava, S., & Mylonakis, E. (2022). Cutaneous complications of mRNA and AZD1222 COVID-19 vaccines: A worldwide review. Microorganisms, 10(3), Article 624.

Das, K., Daveluy, S., Kroumpouzos, G., Agarwal, K., Podder, I., Farnbach, K., Ortega-Loayza, A. G., Szepietowski, J. C., Grabbe, S., & Goldust, M. (2022). Efficacy and toxicity of classical immunosuppressants, retinoids and biologics in hidradenitis suppurativa. Journal of Clinical Medicine, 11(3), Article 670.

Messas, T., Messas, A., & Kroumpouzos, G. (2021). Carbon dioxide laser vulvovaginal rejuvenation: A systematic review. Cosmetics, 8(3), Article 56.

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

Published on by Oncology

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

MPMMCC, HBCH,Tata memorial centreVaranasi | India

AUTHOR PROFILE

GOOGLE SCHOLAR

🎓 EARLY ACADEMIC PURSUITS

Dr. Sadaf Haiyat laid a strong foundation for her medical career at Aligarh Muslim University (AMU), one of India’s premier institutions. She completed her MBBS in 2011 and pursued her MD in Pathology, graduating in 2016 with distinction. Her early education was marked by academic excellence, securing 75.5% in SSSC (10+2) with a distinction in Chemistry, and scoring a 99% merit in Science during high school at Nazareth Academy, Gaya.

🧑‍🏫 PROFESSIONAL ENDEAVORS

Dr. Haiyat has accrued over 11 years of rich experience in Anatomic and Clinical Pathology, including senior roles across reputed institutions such as J.N.M.C.H, AMU, Popular Multispeciality Hospital (Varanasi), Dr. Lal Path Labs (New Delhi), and currently serves as Assistant Professor and Consultant Oncopathologist at the Tata Memorial Centre/MPMMCC, Varanasi.

Her journey has spanned clinical diagnostics, academic teaching, lab administration, and quality assurance. She played a pivotal role in establishing a molecular pathology lab and actively leads EQAS audits and CAP/NABL compliance efforts.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON HEMATOLYMPHOID MALIGNANCY

Dr. Haiyat has significantly contributed to the diagnosis and characterization of hematolymphoid malignancies, integrating morphological, immunohistochemical, molecular, and cytogenetic techniques. She has independently handled bone marrow biopsies, hematopathology diagnostics, and real-time PCR testing, including for EGFR, HER2/neu, and EWSR1 alterations. Her role in initiating molecular diagnostics for precision oncology marks a critical contribution to personalized medicine in resource-optimized settings.

📚 ACADEMIC CONTRIBUTIONS AND CITES

  • Total Publications: 25 (including 19 in international journals)

  • Presentations: 34 papers/posters at national and international platforms

  • Conferences Attended: 44 (10 international, 34 national)

  • Notable Thesis: “Role of Syndecan-1 (CD138) as a Diagnostic Biomarker for Plasma Cells in Patients of Abnormal Uterine Bleeding”

Her research is regularly cited in hematology and oncopathology contexts, particularly for rare case diagnostics and biomarker identification.

🌏 IMPACT AND INFLUENCE

Her academic and diagnostic influence extends internationally, evidenced by:

  • Membership in prestigious bodies such as the International Society of Gynecological Pathology, Association of Molecular Pathology (AMP), and the British Association of Urologic Pathology.

  • Awarded the 2024 Global Pathology Education Award by the College of American Pathologists (CAP) — a global recognition of excellence and commitment to medical education and diagnostics.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Haiyat’s legacy is anchored in diagnostic precision, academic mentoring, and laboratory excellence. With a growing footprint in digital pathology, molecular diagnostics, and oncopathology, she is poised to lead next-generation pathology services, potentially extending to AI-assisted diagnostics, genomics-based therapeutic mapping, and international collaborations in cancer diagnostics.

She also mentors senior residents and scientific assistants, reflecting her commitment to nurturing the next wave of medical professionals.

🔚 CONCLUSION

Dr. Sadaf Haiyat stands out as a visionary pathologist, blending diagnostic expertise with academic vigor and clinical leadership. Her journey from a meritorious student to a recognized name in oncopathology reflects a commitment to excellence, education, and innovation. With a robust foundation, international accolades, and an eye toward the future of molecular and digital pathology, Dr. Haiyat is undeniably shaping the landscape of modern diagnostic medicine in India and beyond.

📊NOTABLE PUBLICATION:

Breast lymphomas: Clinical and pathological insights from a tertiary cancer care center in India
Journal: Indian Journal of Pathology and Microbiology
Year: 2024

Megaloblastic anemia: A common but often neglected cause of pyrexia of unknown origin
Journal: Journal of Translational Internal Medicine
Year: 2015

Epithelioid sarcoma: A diagnostic challenge of a rare presentation
Journal: Archives of International Surgery
Year: 2016

A Survey of Intestinal Lesions with Special Reference to Intestinal Tuberculosis in and Around Uttar Pradesh, India
Journal: International Journal of Current Microbiology and Applied Sciences
Year: 2015

Extradigital Glomus Tumour of Ankle in a Toddler: A Rare Case Report with Unusual Presentation
Journal: Journal of Medical and Surgical Pathology
Year: 2018